Clinical Trial Update: Actual Use and Compliance Study Of Ibuprofen 600 Mg Immediate Release/Extended Release Tablets In At-Risk OTC Consumers [Phase 3]

View source ↗

Summary

Phase 3 trial update on actual use and compliance of ibuprofen 600 mg IR/ER tablets in at-risk OTC consumers; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pain

Drugs mentioned

• Ibuprofen 600 mg Immediate Release/Extended Release (ibuprofen)

Snippet

Sponsor: Pfizer | Conditions: Pain | Phase 3 | Status: TERMINATED | Results posted: 2021-09-24